Allergic Immunotherapy Market 2022 Industry Scenario, Strategies, Growth Factors and Forecast to 2030

SDKI Inc. published a new report on the global allergic immunotherapy market. This study includes the statistical and analytical approaches needed to grow the allergic immunotherapy market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-106118

The allergic immunotherapy market is estimated to reach US $ 7.32 billion by 2030 from a market value of US $ 3.56 billion in 2022 and is expected to grow at a CAGR of 10.85% during the 2022-2030 forecast period.

Allergic immunotherapy avoids allergic reactions caused by fruit, pollen, dust and bee venom. It is a cure for. Among other common allergies, allergic immunotherapy helps control the symptoms of people suffering from allergies such as rhinitis, asthma and conjunctivitis. Immunotherapy for allergies requires daily doses that increase the usual dose to develop the patient's resistance. Due to the improved development of blocking antibodies that fight allergy-inducing foreign compounds, the patient's immune system becomes less vulnerable with gradual dose increases.

Sample URL for the report
https://www.sdki.jp/sample-request-106118

The growth of the allergic immunotherapy market is driven by the prevalence of allergic diseases, increased awareness of allergic treatment, and high clinical research and development costs by governments and nonprofits. Leading players in the global allergy immunotherapy market are adopting a variety of strategies to gain competitive advantage, including product launches, mergers and acquisitions, partnerships and agreements, investments and financing. In October 2017, DBV Technologies signed a contract with Stallergenes S.A. for research and development to prevent birch allergies. In addition, the European Academy of Allergies (EAACI) estimates that more than 150 million people in Europe actually suffer from chronic food allergies, which represents 20 percent of the country's population. Allergic rhinitis and asthma are the most common allergies, affecting 100 million and 70 million people, respectively.

However, the shortage of qualified practitioners and high procedural costs can curb the growth of the allergic immunotherapy market.

Allergic immunotherapy market segment

The allergic immunotherapy market is by treatment (subcutaneous therapy (SCIT), sublingual therapy (SLIT)), by allergy (allergic rhinitis, allergic conjunctivitis, allergic asthma, stinging insect poison, etc.) ), By distribution channel (hospital, e-commerce, pharmacy) and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional Overview of the Allergic Immunotherapy Market

The North American region is a world-leading region. This is due to increased awareness of allergy treatment and high clinical research and development costs by governments and nonprofits. Meanwhile, the Asia Pacific allergic immunotherapy market is expected to show the highest growth rate / CAGR during the 2022-2030 forecast period. Factors such as the prevalence of allergic diseases create favorable growth opportunities for the allergic immunotherapy market in the Asia Pacific region.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Details of the research report
https://www.sdki.jp/reports/global-allergy-immunotherapy-market/106118

Key Players in the Allergy Immunotherapy Market

Key Players in the Allergy Immunotherapy Market include Stallergenes Greer, ALK, Allergy Therapeutics, Merck KGaA, HAL Allergy BV, Biomay AG, Anergis, Aimmune Therapeutics, Circassia and DBV Technologies. I have. The study includes a detailed competitive analysis of these major companies in the allergy immunotherapy market, corporate profiles, recent developments, and key market strategies.

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

This release was published on openPR.